Prosurg's Opal goes on sale:
This article was originally published in Clinica
Prosurg's Opal probe for the treatment of urological and gynaecological disorders is poised for worldwide distribution. The California-based company introduced its outpatient needle ablation electrosurgical device at the recent American Urological Association meeting in Orlando. The probe, which has already received 510(k) clearance from the US FDA, can deliver anaesthetic agents or biomaterials to the tissue prior to radio frequency energy treatment and is compatible with diagnostic endoscopes.